Skip to main content
Clinical Trials/JPRN-UMIN000040923
JPRN-UMIN000040923Not yet recruiting未知

The exploratory study to determine the optimal initial dose of tyrosine kinase inhibitors including combination immunotherapy in individual patients with advanced renal cell carcinoma - To determine the optimal initial dose of tyrosine kinase inhibitors including combination immunotherapy in renal cell carcinoma

Department of Urology, Graduate School of Medicine, Yamaguchi University0 sites100 target enrollmentStarted: July 1, 2020Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
20years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Department of Urology, Graduate School of Medicine, Yamaguchi University

Similar Trials